Segment Reporting - Schedule of Reconciliation of Segment Net Loss (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Segment Reporting [Line Items] | ||||||
| License and collaboration revenues | $ 2,768 | $ 48 | $ 2,937 | $ 48 | ||
| Research and development expense | (16,273) | (8,773) | (31,303) | (15,406) | ||
| General and administrative expense | (4,099) | (4,699) | (8,845) | (9,513) | ||
| Other income, net | 380 | 580 | 637 | 1,809 | ||
| Income tax expense | (60) | (55) | (108) | (109) | ||
| Net loss | (17,284) | $ (19,398) | (12,899) | $ (10,272) | (36,682) | (23,171) |
| Reconciliation of loss: | ||||||
| Net loss | (17,284) | $ (19,398) | (12,899) | $ (10,272) | (36,682) | (23,171) |
| Treatment of Respiratory Diseases Segment | ||||||
| Segment Reporting [Line Items] | ||||||
| Net loss | (17,284) | (12,899) | (36,682) | (23,171) | ||
| Reconciliation of loss: | ||||||
| Net loss | (17,284) | (12,899) | (36,682) | (23,171) | ||
| Operating Segment | Treatment of Respiratory Diseases Segment | ||||||
| Segment Reporting [Line Items] | ||||||
| License and collaboration revenues | 2,768 | 48 | 2,937 | 48 | ||
| Research and development expense | (16,273) | (8,773) | (31,303) | (15,406) | ||
| General and administrative expense | (4,099) | (4,699) | (8,845) | (9,513) | ||
| Other income, net | 380 | 580 | 637 | 1,809 | ||
| Income tax expense | (60) | (55) | (108) | (109) | ||
| Net loss | (17,284) | (12,899) | (36,682) | (23,171) | ||
| Reconciliation of loss: | ||||||
| Net loss | (17,284) | (12,899) | (36,682) | (23,171) | ||
| Adjustments and reconciling items | Treatment of Respiratory Diseases Segment | ||||||
| Segment Reporting [Line Items] | ||||||
| Net loss | 0 | 0 | 0 | 0 | ||
| Reconciliation of loss: | ||||||
| Net loss | $ 0 | $ 0 | $ 0 | $ 0 | ||
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|